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Adenovirus has enormous potential as a gene-therapy vector, but
preexisting immunity limits its widespread application. What is
responsible for this immune block is unclear because antibodies
potently inhibit transgene expression without impeding gene
transfer into target cells. Here we show that antibody prevention
of adenoviral gene delivery in vivo is mediated by the cytosolic
antibody receptor TRIM21. Genetic KO of TRIM21 or a single-
antibody point mutation is sufficient to restore transgene expres-
sion to near-naïve immune levels. TRIM21 is also responsible for
blocking cytotoxic T cell induction by vaccine vectors, preventing
a protective response against subsequent influenza infection and
an engrafted tumor. Furthermore, adenoviral preexisting immunity
can lead to an augmented immune response upon i.v. administra-
tion of the vector. Transcriptomic analysis of vector-transduced tis-
sue reveals that TRIM21 is responsible for the specific up-regulation
of hundreds of immune genes, the majority of which are compo-
nents of the intrinsic or innate response. Together, these data
define a major mechanism underlying the preimmune block to
adenovirus gene therapy and demonstrate that TRIM21 efficiently
blocks gene delivery in vivo while simultaneously inducing a rapid
program of immune transcription.
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Adenoviral vectors are the most frequently used delivery vehi-cles in gene therapy clinical trials (1) and have enormous
potential as vaccine vectors and oncolytic agents in cancer treat-
ment (2). They are attractive because they can be grown to high
titers, their genome sequence can easily be manipulated, and they
induce robust transgene expression in a variety of dividing and
nondividing cell types. Despite these advantageous properties, the
high level of preexisting immunity in the human population pre-
vents their widespread use. This is particularly true for adenovirus 5
(Ad5) (3–5), the subtype on which most adenoviral vectors have
been based. Preexisting humoral immunity is a correlate of poor
transgene expression (6) and, during vaccination, a subsequently
diminished CD8 T cell response against the desired antigen (6–9).
Therefore, knowing what mediates the block to transgene expres-
sion and activates the immune response in the presence of anti-Ad5
antibodies might provide insight into new approaches to circumvent
preexisting immunity. The majority of anti-Ad5 neutralizing Abs
(NAbs) are directed against the major coat protein hexon (5, 10,
11), and more specifically its solvent-exposed hypervariable regions
(HVRs) (12). As hexon is not involved in the coxsackie and ade-
novirus receptor (CAR)-dependent entry mechanism that Ad5 uses,
which is mediated by fiber and penton base (13, 14), the neutralizing
effect is unlikely to involve classical entry blocking.
We have previously shown that the cytosolic antibody receptor
TRIM21 mediates the efficient cytosolic neutralization of
antibody-bound Ad5 in vitro. Ad5 gains access to the cytosol
during infection through penetration of early endosomes shortly
after endocytosis and can therefore carry antibody into the cy-
tosol. Upon binding to the Fc region of IgG with its PRYSPRY
motif, TRIM21 becomes activated and sequentially recruits the
E2 enzymes Ube2W and Ube2N/Ube2V2, which N-terminally
polyubiquitinate TRIM21 with anchored K63 chains. This results
in recruitment of the proteasome and rapid degradation of the
viral particle while, simultaneously, the proteasome-associated
deubiquitinase PohI liberates the K63-linked ubiquitin chains,
which stimulate innate immune signaling pathways (15–18). Fur-
thermore, degradation of the viral capsid results in the exposure of
the Ad5 DNA to the cytosolic DNA sensor cGAS, which can
initiate a second wave of innate immune signaling (19).
Here we investigate what role TRIM21 has in the preexisting
immune block to Ad5 gene delivery in vivo and in the activation
of innate immune signaling.
Results
As hexon is the immunodominant antigen in preexisting Ad5
immunity, we chose as a model the anti-hexon mouse–human
chimeric IgG1 monoclonal antibody (mAb) 9C12 (rh9C12),
which binds two of the hexon HVRs (20). First, we investigated
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whether vector uptake in vivo was inhibited by rh9C12 via a
receptor-blocking effect. Mice were injected with rh9C12 2–4 h
before injection with Ad5 to mimic circulating humoral immu-
nity to the virus. Livers were harvested 2–8 h postinfection, and
quantitative PCR (qPCR) was used to quantify viral genomes
within the tissue. At no time point did we observe a difference in
genome delivery in the presence of antibody (Fig. 1A). To assess
whether rh9C12 diminishes transgene expression, we looked at
liver transduction by Ad5 carrying the luciferase gene (Ad5-Luc)
and found that, although rh9C12 did not affect viral gene
transfer, it diminished transgene expression 1,000-fold (Fig. 1C).
A possible explanation for this observed discrepancy is that the
presence of antibody alters transgene expression by changing the
entry route of virus into cells and preventing access to the cy-
tosol. Antibody has previously been shown to allow uptake by
liver-resident Kupffer cells by engaging FcγRs (21), which might
result in decreased infection. We produced a “LALA” (L234A/
L235A) mutant of rh9C12, which significantly diminishes FcγR
binding by ablating the binding site (Fig. 1B) (22). The LALA
mutation had no measurable impact on the block to transgene
expression by rh9C12 (Fig. 1C), indicating that antibody in-
hibition is not the result of rerouting virus to a noninfectious and
FcγR-dependent cell entry pathway.
As we have previously demonstrated that TRIM21 mediates
potent postentry neutralization of Ad5 in cells (20, 23, 24), we
sought to determine whether TRIM21 is responsible. We pro-
duced a further variant of rh9C12 with mutation H433A, which
ablates the interaction with TRIM21 (24). Remarkably, H433A
almost completely abolished the antibody block to Ad5 trans-
gene expression in the liver (Fig. 1D). Although the TRIM21
binding site is distinct from that of FcγRs, it does overlap with
that of the neonatal Fc receptor (FcRn) (Fig. 1B). To ensure that
the phenotype we observed is not caused by a shorter serum t1/2
as a result of poorer FcRn-mediated recycling, we determined
that mouse FcRn binds WT rh9C12 and H433A with similar
efficiency (SI Appendix, Fig. S1 A and B). Furthermore, no dif-
ference in the serum levels of these antibodies was detected 24 h
post injection (SI Appendix, Fig. S1C), showing that there has been
no alteration in FcRn recycling, in accordance with previous reports
(25). We sought to confirm this result genetically by repeating the
experiment with WT rh9C12 in Trim21 KO mice. Although overall
transduction levels in both strains were comparable (SI Appendix,
Fig. S2A), the T21-KO mice given rh9C12 closely phenocopied WT
mice given the H433A mutant in liver and spleen (Fig. 1D).
Finally, we sought to determine whether TRIM21 blocks gene
delivery in the presence of a polyclonal antibody response. We
raised anti-serum against Ad5 and found that, although it did not
diminish gene transfer (Fig. 1E), it blocked transgene expression
(Fig. 1F). At antibody dilutions sufficiently low to inhibit sig-
nificantly, the effect was TRIM21-dependent. Western blot
analysis revealed that the polyclonal serum contained mainly
anti-hexon antibodies, but also anti-fiber and low levels of anti-
penton base antibodies (SI Appendix, Fig. S3 A and B), indicating
that TRIM21 neutralizes in the presence of antibodies against
multiple epitopes. To specifically discern the neutralization ac-
tivity of anti-fiber antibodies, we assessed gene delivery in the
presence of the mouse monoclonal anti-fiber antibody 4D2.
Although 4D2 reduced gene delivery (SI Appendix, Fig. S3C), the
inhibition was only 10-fold, compared with almost 1,000-fold in
the case of the anti-hexon monoclonal 9C12. Moreover, there
was no TRIM21 contribution (SI Appendix, Fig. S3C), which is
consistent with Ad5 biology, as fiber is shed during Ad5 entry
and is therefore not associated with the Ad5 capsid in the cytosol
(13, 14, 26). Taken together, these data strongly suggest that
TRIM21 is responsible for the highly potent block to adenoviral
gene delivery by the antibody component of preexisting immu-
nity. Moreover, our data support previous research demon-
strating that, although a natural immune response to adenovirus
infection elicits anti-fiber and anti-hexon NAbs, the anti-fiber
NAbs are less potent than anti-hexon NAbs (11).
In primates and rodents, Ad5 is taken up by multiple cell
types, including Kupffer cells and hepatocytes. As TRIM21 is
widely expressed in almost all tissues, it may be contributing to
responses in both cell types. Upon initial administration of Ad5,
the mononuclear phagocytic system acts to clear virus before it
can infect the liver parenchyma (27). We therefore sought to
deplete macrophages before Ad5 infection to discriminate
TRIM21-dependent neutralization in these cells from neutrali-
zation in hepatocytes. To this end, we depleted Kupffer cells with
clodronate liposomes before Ad5 administration, using markers
Adgre1 and Clec4f to confirm depletion (SI Appendix, Fig. S4A).
Clodronate-treated mice also had a reduced response to LPS,
confirming functional depletion (SI Appendix, Fig. S4B). As treat-
ment with PBS liposomes also slightly attenuated the inflammatory
response while not affecting macrophage levels, we used PBS only
as our control in subsequent experiments. Macrophage depletion
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Fig. 1. Diminished transgene expression in the presence of anti-Ad5 anti-
bodies is mediated by TRIM21. (A) Viral copy number at the indicated time
points postinfection. (B) Model of human IgG1. Key residues involved in
binding to FcγRs are depicted in red (L234/L235), and the TRIM21- and FcRn-
binding sites are depicted in blue (H433 in light blue, N434 and H435 in dark
blue). (C) Relative infection of Ad5-Luc in mouse liver in WT animals using
2.5 μg WT rh9C12 and FcγR-binding mutant LALA. (D) Relative infection of
Ad5-Luc in mouse liver (Left) and spleen (Right) in WT and T21-KO animals
using 1 μg WT rh9C12 and TRIM21 nonbinding mutant H433A. (E) Viral copy
number 4 h postinfection with anti-Ad5 immune serum (diluted 1:500). (F)
Relative infection of Ad5-Luc in mouse liver using the indicated dilutions of
anti-Ad5 immune serum in WT and T21-KO animals. (G) Absolute levels of
infection measured in relative light units (RLUs) in clodronate-treated or
control mice. (H) Relative infection in clodronate-treated or control mice
using 1 μg WT rh9C12 and TRIM21 nonbinding mutant H433A. Error bars
depict mean ± SEM. Groups consisted of n = 3–10 mice.
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48 h before Ad5 infection increased transgene expression (Fig.
1G), consistent with their known role in clearing virus and limiting
transduction. The greatest impact was seen at a lower viral dose of
109, with eightfold higher transgene expression in clodronate-
treated animals. This is consistent with macrophages preferentially
taking up virus but becoming saturated at a high viral dose, allowing
productive transduction of hepatocytes. This finding is in agreement
with previous reports of a nonlinear dose–response relation in mice
given sequential doses of Ad5, whereby the first dose was shown to
saturate Kupffer cells, allowing more virions in the second dose to
productively infect hepatocytes (28). When mice were infected with
Ad5-Luc in the presence of WT rh9C12, transgene expression was
strongly reduced in PBS- and clodronate-treated mice (Fig. 1H).
This reduction was largely TRIM21-dependent in both conditions
and suggests that TRIM21 can efficiently block gene delivery in
hepatocytes, independent from neutralization in macrophages.
Efficient gene delivery is important in adenovirus-based vac-
cines, which are used to deliver T cell epitopes and induce a
cytotoxic CD8 T cell response. A TRIM21-dependent block to
transgene expression might be expected to severely limit CD8
induction, but activation of TRIM21 also results in potent im-
mune stimulation (21), which could have the opposite effect.
Therefore, to test the impact of TRIM21 on the induction of
cytotoxic T cells (CTLs) by Ad5 vectors, we made use of the
ovalbumin antigen-presentation model system. Ovalbumin con-
tains the immunodominant CD8 T cell epitope SIINFEKL
(SL8), and anti-SL8 CTLs can be quantified after immunization
by using specific MHC class I tetramers. We analyzed the per-
centage of SL8-specific T cells 10 d after infection with an Ad5
ovalbumin transgene vector (Ad5-Ova). We observed strong
induction of SL8-specific T cells in i.v. immunized animals, which
was reduced almost two orders of magnitude, to PBS control
levels, in the presence of WT rh9C12 (Fig. 2A). Importantly, and
in contrast to WT antibody, the H433A mutant did not signifi-
cantly reduce antigen-specific CTL induction. We obtained
similar results upon vaccination of T21-KO mice, confirming that
TRIM21 represents a significant block to CTL induction (Fig.
2B). However, i.v. administration is only one possible immuni-
zation route, and it has been shown that intranasal administra-
tion of Ad5 can circumvent preexisting immunity in nonhuman
primates (29). To test this in our model, we intranasally ad-
ministered the same viral dose as in i.v. injections (SI Appendix,
Fig. S5A). We observed markedly reduced induction of SL8-
specific CD8 T cells compared with i.v. administration of Ad5-
Ova, but no inhibition by rh9C12-WT.
Influenza causes seasonal epidemics and is a key focus of
vaccine efforts. We therefore investigated whether TRIM21
would significantly inhibit an i.v.-administered adenovirus-based
vector designed to vaccinate against flu infection. We con-
structed a variant of the influenza virus A/Puerto Rico/8/1934/
(H1N1) strain in which the SL8 peptide (ovalbumin residues
257–264) was incorporated into the stalk of the viral neuramin-
idase protein (PR8-SL8). Next, we immunized mice i.v. with the
Ad5-Ova vector and, 10 d later, administered PR8-SL8 in-
tranasally. Three days after flu infection, we measured viral
replication in the lungs by qPCR. Animals that had been vacci-
nated with Ad5-Ova had a significantly lower viral burden
compared with those in the control nonvaccinated group (Fig.
2C). Animals that had been vaccinated with Ad5-Ova in the
presence of WT rh9C12 had similar levels of flu in their lungs as
nonvaccinated controls, demonstrating that the antibody had
ablated any benefit from vaccination. By comparison, the H433A
mutant did not prevent effective Ad5-Ova vaccination, as these
animals were able to reduce flu levels similarly to animals given
Ad5-Ova alone.
As the overall reductions in PR8 viral titer achieved by im-
munization were modest, we established a second model system
in which to investigate the TRIM21 block to Ad5 vaccination.
We immunized WT or T21-KO animals with Ad5-Ova alone and
in the presence of rh9C12-WT or H433A mutant. Seven days
later, animals underwent skin graft with the fibrosarcoma tumor
cell line MCA101 secreting ovalbumin (30, 31). Growth of the
tumor was monitored regularly by calculating the increase in
volume. Rapid tumor growth was observed in nonimmunized
animals, with a nonsignificant difference between genotypes.
Animals that had been vaccinated with Ad5-Ova displayed sig-
nificantly reduced tumor growth; however, in WT mice vacci-
nated with Ad5-Ova in the presence of WT rh9C12, there was
only a mild and nonsignificant reduction in tumor growth com-
pared with nonimmunized animals (Fig. 2D). This is consistent
with a potent antibody block to Ad5-Ova vaccination. Impor-
tantly, T21-KO mice immunized with Ad5-Ova in the presence
of WT rh9C12 were able to control tumor growth as effectively
as those immunized with virus alone. Therefore, TRIM21 an-
tagonizes effective adenovirus vaccination in the context of an-
tiviral and antitumor immunity.
Although the major problem of preexisting immunity to Ad5 is
the block to transgene expression, a second problem is that it can
elicit an immune response upon vector administration. Studies of
the signaling response to Ad5 vectors in the context of preex-
isting immunity report varying responses depending on what cell
type or tissue was analyzed (6, 32, 33). To determine the impact
of Ad5 antibody on immune signaling during gene delivery in our
experiments, we measured the transcriptional changes in a panel
of cytokines, NF-κB target genes, and IFN-stimulated genes
(ISGs). We quantified transcriptional changes in the liver at a
range of time points postinfection (Fig. 3A). Overall, the data
show that, at 2, 4, 6, and 8 h after i.v. Ad5 administration, cy-
tokine induction in the presence of antibody is considerably
stronger, indicating that antibody promotes an inflammatory
response. Although the induction of NF-κB target genes and
type I IFN was already observed at 2 h postinfection, the ISGs
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Fig. 2. TRIM21 blocks antigen-specific CD8 T cell responses in an antibody-
dependent manner. (A) SIINFEKL (SL8)-specific CD8 T cell frequency in the
blood of mice i.v. immunized with Ad5-Ova [108 particles (pts)] in the pres-
ence of WT rh9C12 or H433A. (B) SIINFEKL (SL8)-specific CD8 T cell frequency
in the blood of WT and T21-KO mice immunized with Ad5-Ova in the
presence of WT rh9C12. Error bars depict mean ± SEM. Groups consisted of
n = 4–5 mice. (C) Mice were immunized with Ad5-Ova with or without WT
rh9C12 or H433A and infected with PR8-SL8 on day 10 post immunization.
Viral titer in the lung was determined 3 d postinfection by qPCR. Error bars
depict mean ± SEM. Groups consisted of n = 5–6 mice. (D) WT (Left) or T21-
KO (Right) animals were immunized with Ad5-Ova only or in the presence of
WT rh9C12 and injected with MCA-ovalbumin tumor cells on day 7 post
immunization. Error bars depict mean ± SEM. Groups consisted of n = 5–8
mice. Tumor growth curves were analyzed by comparing area under the
curve by one-way ANOVA with a Tukey post hoc test.
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Mx1 and Isg15 were up-regulated only from 4 h postinfection.
We obtained similar data by using polyclonal anti-Ad5 sera,
confirming that the signaling response was independent of epi-
tope specificity (Fig. 3B). Importantly, the transcriptional
changes evoked by virus and antibody were of similar magnitude
as those induced 4 h after challenge with the TLR7 agonist
resiquimod or TLR9 agonist CpG (SI Appendix, Fig. S6A). These
results underline the biological significance of the signaling re-
sponse to Ad5 induced by antibody. Moreover, use of the H433A
mutant or T21-KO mice demonstrated that TRIM21 contributes
to the antibody stimulation of immune signaling (Fig. 3C). In five
of the six genes analyzed, we observed no additive effect of
H433A and Trim21 KO, indicating that TRIM21’s role in im-
mune signaling is solely antibody-dependent.
To further investigate the role of TRIM21 in activating im-
munity and determine the exact nature of the transcriptional
program that TRIM21 mediates upon infection, we analyzed
genome-wide differential gene expression by RNA sequencing
(RNA-seq). First, we determined whether TRIM21 requires
antibody to alter transcription during infection. Strikingly, we
found that, in uninfected animals or animals infected with Ad5
alone, KO of Trim21 had minimal impact on gene expression,
whereas infection in the presence of rh9C12-WT resulted in al-
most 700 differentially expressed genes between the genotypes
(Fig. 4A). Comparison of WT and T21-KO mice infected in the
presence of rh9C12-H433A revealed only nine differentially
expressed genes, supporting the previous observation of no ad-
ditive effect of H433A and Trim21 KO (SI Appendix, Fig. S6B).
Thus, TRIM21 does not possess gene-regulatory activity during
infection outside of its function as an antibody receptor. This is a
key finding given that nonantibody-dependent immune functions
have been proposed for TRIM21, specifically negative regulatory
roles through interaction with IRF3 (34), IRF7 (35), and
DDX41 (36).
To determine the specific contribution TRIM21 makes to
immune signaling during viral challenge, we analyzed the total
transcriptional changes induced by Ad5 infection. We found 995
differentially expressed genes [false discovery rate (FDR)-ad-
justed P < 0.05] between uninfected and infected WT mice, with
574 being up-regulated and 421 being down-regulated. A total of
31.9% of these genes could be classified as immune genes (Fig.
4B and Dataset S1) and were largely up-regulated. Within these
immune genes, the most up-regulated group consisted of acute
phase proteins, such as C-reactive protein and the serum amyloid
A family. Furthermore, there was a strong innate immune re-
sponse, with intrinsic immunity, innate immune signaling, and
innate immune sensors constituting 32.8% of the overall immune
response.
Next, we investigated how the antiviral immune response is
altered in the presence of antibody (Fig. 4C). We isolated all
significantly differentially expressed genes (FDR-adjusted P <
0.05) between WT mice infected with Ad5 alone or in the
presence of rh9C12-WT and focused on immune annotated
genes [based on Gene Ontology (GO) term: immune system
process, GO:0002376]. Infection in the presence of WT rh9C12
induced the strongest response in this group, as indicated by the
largest row Z-scores, with the majority of genes being expressed
at the highest level in this condition. Notably, several genes that
were strongly antibody-induced when measured by qPCR, such
as Cxcl10, Mx1, Cxcl1, and Isg15 (Fig. 3C), were among those
most highly expressed upon stimulation with Ad5 and rh9C12-
WT in this transcriptome-wide analysis. The data suggest that a
component of antibody dependent stimulation is TRIM21-
mediated, as the expression of this immune gene set between virus
only and virus + rh9C12-H433A was more similar than between
virus + rh9C12-WT and virus + rh9C12-H433A. However, al-
though the row Z-scores reveal a trend of transcriptional changes
suggestive of immune up-regulation by TRIM21, they do not
imply statistical significance. To determine whether the changes in
gene expression induced by TRIM21 are statistically significant,
we analyzed the TRIM21-dependent differential gene expression
(FDR-adjusted P < 0.05). We employed two different compari-
sons to determine the TRIM21-dependent transcriptional changes
and compared differential gene expression between Ad5 +
rh9C12-WT inWT and T21-KO animals as well as between Ad5 +
rh9C12-WT and Ad5 + rh9C12-H433A in WT animals (Fig. 4D).
In each group, we found more than 600 genes that were statisti-
cally significantly differentially expressed (984 genes in total), of
which 416 occurred in both comparisons. Thus, there is a consis-
tent statistically significant effect when perturbing TRIM21 func-
tion genetically or at the level of protein–protein interaction
with antibody.
The TRIM21-dependent transcriptional changes demonstrate
its role as a positive immune regulator. Detailed analysis
revealed that 43.9% of the differentially regulated genes could
be classified as immune genes (Fig. 4D and Dataset S2), whereas
the remaining 56.1% consisted of genes related to common
cellular processes. The vast majority of genes influenced by
TRIM21 were up-regulated. Crucially, the only genes down-
regulated by TRIM21 were involved in metabolism. Focusing
on the immune genes, we found that TRIM21 initiated a strong
innate immune response, with intrinsic immunity, innate immune
signaling, and innate immune sensors accounting for 49.8% of
the up-regulated immune genes. Importantly, the pattern of
TRIM21-dependent gene expression was different from that
induced by virus only (Fig. 4 B and D). This indicates that
TRIM21 does not amplify all transcriptional changes induced
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Fig. 3. Anti-Ad5 antibodies elicit a potent inflammatory response. (A) Fold
induction of cytokines in mouse liver at the indicated time points in response
to Ad5 alone (2 × 1010 pts) or Ad5 and WT rh9C12. (B) Fold induction of the
indicated cytokines in response to Ad5 alone or and Ad5 and anti-Ad5 im-
mune serum 4 h postinfection. (C) Fold induction of the indicated cytokines
in the liver of WT (black bars) and T21-KO (gray bars) mice 4 h postinfection.
Error bars depict mean ± SEM. Groups consisted of n = 3–5 mice.
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by virus alone, but rather that it fine-tunes the immune re-
sponse and focuses it toward a more innate response. This may
reflect that TRIM21 is a component of intrinsic rather than
cellular immunity.
Discussion
Adenovirus is an attractive vector for gene therapy and vacci-
nation, but preexisting immunity provides a major obstacle to its
widespread use. This is because of the high prevalence of pre-
existing immunity in the population, which dramatically reduces
transgene expression. It has been unclear exactly how antibodies
block Ad5 transduction, as they do not block uptake of vector
into cells of diverse tissues (6). Here we show that anti-Ad5
antibodies block transgene expression via the intracellular Fc
receptor TRIM21. Cytosolic neutralization by TRIM21 explains
the previous discrepancy between genome uptake and transgene
expression. Furthermore, we show that TRIM21 inhibits the
induction of antigen-specific CTLs, which prevents model Ad5
vaccines from inducing protective downstream antiviral and an-
titumor immunity. This is an interesting finding given that, while
TRIM21 reduces transgene expression, it simultaneously boosts
immune signaling, which might stimulate a CD8 T cell response.
A potential aspect of TRIM21 function we have not investigated
here is whether TRIM21 could contribute to the induction of a
CD8 T cell response against structural proteins of the vector. It
has previously been shown that cellular immunity does not re-
quire de novo translation of viral proteins (37), and because
TRIM21 action results in rapid and specific proteasomal deg-
radation of the viral capsid, this could facilitate TAP-mediated
transfer of peptides into the endoplasmic reticulum and there-
fore enhance MHC class I presentation of vector antigens.
A further potential problem caused by preexisting immunity
during Ad5 gene therapy is the induction of a transgene-
independent immune response (38). There are conflicting reports,
which vary from observing increased serum cytokine levels
(6, 32), strong liver toxicity (39), and even animal death (32)
in the presence of anti-Ad5 antibodies to decreased toxicity
(40) and attenuated cytokine induction in peripheral blood
mononuclear cells (33). Our data show that, after i.v. admin-
istration of Ad5, immune signaling is strongly induced in the
presence of anti-Ad5 antibody and that a significant part of
this signaling is TRIM21-dependent. We found that, al-
though not up-regulating a unique set of genes, TRIM21 fine-
tunes the immune response already evoked by virus alone and
focuses it toward a stronger innate and intrinsic immune re-
sponse. Gene therapy clinical trials suggest that the problem of
preexisting immunity can be circumvented through a lower viral
dose and local administration (41, 42). Consistent with this, we
observed a reduced block to CD8 cell induction by antibodies and
TRIM21 when vector was given intranasally. However, under
naïve conditions, T cell induction upon intranasal administration
was ∼10-fold weaker than via the i.v. route, suggesting that it may
be more beneficial to block preexisting immunity than alter de-
livery regimen. The identification of TRIM21 as a major player in
the preexisting immune block to adenovirus gene therapy high-
lights the importance of understanding how this cytosolic protein
is activated and regulated. In doing so, we can hope to augment its
activity when advantageous or disrupt it when beneficial.
Materials and Methods
Animal Procedures. All animal work was licensed under the UK Animals
(Scientific Procedures) Act 1986 and approved, together with human cell
work, by the Medical Research Council Animal Welfare and Ethical Review
Body. C57BL/6 WT (T21+/+) and TRIM21-deficient mice (T21−/−) were obtained
from Jackson Laboratories. Ad5 injections at the indicated dose were admin-
istered in 100 μL endotoxin-free PBS by lateral tail vein injection (i.v.) or in 20
μL by intranasal administration. PR8 infections were by intranasal adminis-
tration of 103 pfu PR8-SL8 in 20 μL endotoxin-free PBS (Teknova) 10 d after
immunization with Ad5-Ova. Details of PR8-SL8 are provided in SI Appendix,
Supplementary Materials and Methods. For challenge with TLR agonists, mice
were injected with 50 μg of resiquimod (R848; Invivogen) and 50 μg CpG (ODN
2395; Invivogen) in 100 μL endotoxin-free water and culled 4 h post injection.
Ex Vivo Viral Assays. Relative infection was calculated from the luciferase
signal from indicated tissues (RLUs virus+antibody/RLUs virus only). Tran-
scriptional changes were determined by qPCR. T cell assays were carried out
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on specific CD8a cells by H-2Kb-SIINFEKL tetramer staining. Further details
are provided in SI Appendix, Supplementary Materials and Methods.
Tumor Growth Experiments. A total of 2.5 × 105 MCA101 cells stably trans-
fected with a plasmid encoding secreted ovalbumin (provided by Clotilde
Théry, Institut Curie, PSL Research University, INSERM U932, Paris) were in-
jected s.c. into mice, and tumor growth was monitored by regular volume
measurement: (length*width2)/2.
Liver Macrophage Depletion.Mice were given 100 μL of clodronate liposomes
(Liposoma) or PBS control by i.v. Virus or LPS (420 μg per mouse) was given
48 h after liposome injection.
Elisa. Hexon and FcRn binding was determined by capture on coated plates
(Bio-Rad) and serum levels of rh9C12 by anti-Fc plates (Southern Biotech). Full
details are provided in SI Appendix, Supplementary Materials and Methods.
Surface Plasmon Resonance. Surface plasmon resonance was performed by
using a BIAcore T200 instrument (GE Healthcare). The Langmuir 1:1 ligand-
binding model provided by the BIAevaluation software was used to de-
termine binding kinetics. Full details are provided in SI Appendix, Supple-
mentary Materials and Methods.
RNA-Seq. RNA-seq library preparation was performed by using the TruSeq
stranded mRNA Library Prep kit (Illumina) according to the manufacturer’s
instructions. A minimum of 20 million reads (SE50) was obtained per sample
on a HiSeq 4000 system (Illumina). Sequencing as well as sequence demul-
tiplexing of samples according to barcodes was performed at the CRUK
Genomics Core, Cambridge, United Kingdom. Further details are provided in
SI Appendix, Supplementary Materials and Methods.
Statistical Analysis. Unless otherwise indicated, statistical analyses were
performed by using GraphPad Prism 7 software (GraphPad). Error bars
depict the SD or SEM as indicated. Unless otherwise indicated, statistical
significance was calculated by using an unpaired, two-tailed Student’s
t test. Statistical significance is depicted at the levels of P ≤ 0.05, P ≤ 0.01,
and P ≤ 0.001.
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